Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: A randomized noninferiority trial versus torasemide immediate release

Alex Roca-Cusachs; Joaquín Aracil-Vilar; Carlos Calvo-Gómez; José Vicente Vaquer-Pérez; Félix Laporta-Crespo; María José Rojas-Serrano; Antonio Guglietta; Savion Gropper; Nadezhda Alexeeva; Pedro Aranda; Josep Lluis Ballvé; Andrei Baranovsky; Svetlana Boldueva; Carles Brotons; Angel Cano; Svetlana Churina; Antoni Coca; Luis De Teresa; Juan Antonio Divisón; Yanis Dumpis; Xavier Farrés; Ángela Felip; Juan García; Blas Gil; Boris Goloschekin; Pablo Gómez; Victor Kostenko; Enrique López De Coca; Manuel Luque; Emili Marco; Joan Martorell; Viktor Milyagin; Alexander Orlov-Morozov; Vladimir Parfenov; Elena Pavlysh; Jaume Plana; Miguel Ángel Prieto; Montserrat Pujol; José Carlos Rodríguez; Alexander Sherenkov; Javier Sobrino; Lev Sorokin; Joaquim Vilà; Irina Zobenko; Konstantin Zrazhesvsky

doi:10.1111/j.1527-3466.2008.00046.x

Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: A randomized noninferiority trial versus torasemide immediate release

Alex Roca-Cusachs, Joaquín Aracil-Vilar, Carlos Calvo-Gómez, José Vicente Vaquer-Pérez, Félix Laporta-Crespo, María José Rojas-Serrano, Antonio Guglietta, Savion Gropper, Nadezhda Alexeeva, Pedro Aranda, Josep Lluis Ballvé, Andrei Baranovsky, Svetlana Boldueva, Carles Brotons, Angel Cano, Svetlana Churina, Antoni Coca, Luis De Teresa, Juan Antonio Divisón, Yanis DumpisXavier Farrés, Ángela Felip, Juan García, Blas Gil, Boris Goloschekin, Pablo Gómez, Victor Kostenko, Enrique López De Coca, Manuel Luque, Emili Marco, Joan Martorell, Viktor Milyagin, Alexander Orlov-Morozov, Vladimir Parfenov, Elena Pavlysh, Jaume Plana, Miguel Ángel Prieto, Montserrat Pujol, José Carlos Rodríguez, Alexander Sherenkov, Javier Sobrino, Lev Sorokin, Joaquim Vilà, Irina Zobenko, Konstantin Zrazhesvsky

Departament de Medicina

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

10 Cites (Scopus)

Resum

The efficacy of a new torasemide prolonged release (PR) formulation to torasemide immediate release (IR) was compared in a randomized noninferiority double-blind trial. Patients with newly diagnosed mild-to-moderate hypertension or unresponsive or poor tolerability to previous antihypertensive monotherapy received 5 mg/day of torasemide-PR (n = 219) or torasemide-IR (n = 223) for 12 weeks (uptitration to 10 mg/day if no response at 4 or 8 weeks). Mean diastolic blood pressure (DBP) reduction in the torasemide-PR group (11.6 ± 7.1 mmHg, 95% confidence interval [CI] 10.6-12.5) versus torasemide-IR (11.3 ± 7.5 mmHg, 95% CI 10.2-12.3) met the noninferiority criterion of a nonsided 97.5% CI lower than the preestablished margin of 2 mmHg. A significantly higher percentage of patients in the torasemide-PR group achieved adequate BP control after 8 and 12 weeks. Ambulatory 24-h BP monitoring (ABPM) measurements in a subset of 100 patients showed greater daytime SBP reductions in the torasemide-PR group (128.4 ± 9.9 mmHg vs. 133.5 ± 10.4 mmHg, P < 0.05). Safety and tolerability of both formulations were similar. © 2008 The Authors.

Idioma original	Anglès
Pàgines (de-a)	91-100
Revista	Cardiovascular Therapeutics
Volum	26
Número	2
DOIs	https://doi.org/10.1111/j.1527-3466.2008.00046.x
Estat de la publicació	Publicada - 14 de jul. 2008

Accés al document

10.1111/j.1527-3466.2008.00046.x

Com citar-ho

Roca-Cusachs, A., Aracil-Vilar, J., Calvo-Gómez, C., Vaquer-Pérez, J. V., Laporta-Crespo, F., Rojas-Serrano, M. J., Guglietta, A., Gropper, S., Alexeeva, N., Aranda, P., Ballvé, J. L., Baranovsky, A., Boldueva, S., Brotons, C., Cano, A., Churina, S., Coca, A., De Teresa, L., Divisón, J. A., ... Zrazhesvsky, K. (2008). Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: A randomized noninferiority trial versus torasemide immediate release. Cardiovascular Therapeutics, 26(2), 91-100. https://doi.org/10.1111/j.1527-3466.2008.00046.x

@article{efca7abe00634ab2b95f69720adf9e2f,

title = "Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: A randomized noninferiority trial versus torasemide immediate release",

abstract = "The efficacy of a new torasemide prolonged release (PR) formulation to torasemide immediate release (IR) was compared in a randomized noninferiority double-blind trial. Patients with newly diagnosed mild-to-moderate hypertension or unresponsive or poor tolerability to previous antihypertensive monotherapy received 5 mg/day of torasemide-PR (n = 219) or torasemide-IR (n = 223) for 12 weeks (uptitration to 10 mg/day if no response at 4 or 8 weeks). Mean diastolic blood pressure (DBP) reduction in the torasemide-PR group (11.6 ± 7.1 mmHg, 95% confidence interval [CI] 10.6-12.5) versus torasemide-IR (11.3 ± 7.5 mmHg, 95% CI 10.2-12.3) met the noninferiority criterion of a nonsided 97.5% CI lower than the preestablished margin of 2 mmHg. A significantly higher percentage of patients in the torasemide-PR group achieved adequate BP control after 8 and 12 weeks. Ambulatory 24-h BP monitoring (ABPM) measurements in a subset of 100 patients showed greater daytime SBP reductions in the torasemide-PR group (128.4 ± 9.9 mmHg vs. 133.5 ± 10.4 mmHg, P < 0.05). Safety and tolerability of both formulations were similar. {\textcopyright} 2008 The Authors.",

keywords = "Diuretic, Hypertension, Toresamide, Toresamide prolonged released",

author = "Alex Roca-Cusachs and Joaqu{\'i}n Aracil-Vilar and Carlos Calvo-G{\'o}mez and Vaquer-P{\'e}rez, {Jos{\'e} Vicente} and F{\'e}lix Laporta-Crespo and Rojas-Serrano, {Mar{\'i}a Jos{\'e}} and Antonio Guglietta and Savion Gropper and Nadezhda Alexeeva and Pedro Aranda and Ballv{\'e}, {Josep Lluis} and Andrei Baranovsky and Svetlana Boldueva and Carles Brotons and Angel Cano and Svetlana Churina and Antoni Coca and {De Teresa}, Luis and Divis{\'o}n, {Juan Antonio} and Yanis Dumpis and Xavier Farr{\'e}s and {\'A}ngela Felip and Juan Garc{\'i}a and Blas Gil and Boris Goloschekin and Pablo G{\'o}mez and Victor Kostenko and {De Coca}, {Enrique L{\'o}pez} and Manuel Luque and Emili Marco and Joan Martorell and Viktor Milyagin and Alexander Orlov-Morozov and Vladimir Parfenov and Elena Pavlysh and Jaume Plana and Prieto, {Miguel {\'A}ngel} and Montserrat Pujol and Rodr{\'i}guez, {Jos{\'e} Carlos} and Alexander Sherenkov and Javier Sobrino and Lev Sorokin and Joaquim Vil{\`a} and Irina Zobenko and Konstantin Zrazhesvsky",

year = "2008",

month = jul,

day = "14",

doi = "10.1111/j.1527-3466.2008.00046.x",

language = "English",

volume = "26",

pages = "91--100",

journal = "Cardiovascular Therapeutics",

issn = "1755-5914",

publisher = "John Wiley and Sons Inc",

number = "2",

}

Roca-Cusachs, A, Aracil-Vilar, J, Calvo-Gómez, C, Vaquer-Pérez, JV, Laporta-Crespo, F, Rojas-Serrano, MJ, Guglietta, A, Gropper, S, Alexeeva, N, Aranda, P, Ballvé, JL, Baranovsky, A, Boldueva, S, Brotons, C, Cano, A, Churina, S, Coca, A, De Teresa, L, Divisón, JA, Dumpis, Y, Farrés, X, Felip, Á, García, J, Gil, B, Goloschekin, B, Gómez, P, Kostenko, V, De Coca, EL, Luque, M, Marco, E, Martorell, J, Milyagin, V, Orlov-Morozov, A, Parfenov, V, Pavlysh, E, Plana, J, Prieto, MÁ, Pujol, M, Rodríguez, JC, Sherenkov, A, Sobrino, J, Sorokin, L, Vilà, J, Zobenko, I & Zrazhesvsky, K 2008, 'Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: A randomized noninferiority trial versus torasemide immediate release', Cardiovascular Therapeutics, vol. 26, núm. 2, pàg. 91-100. https://doi.org/10.1111/j.1527-3466.2008.00046.x

Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: A randomized noninferiority trial versus torasemide immediate release. / Roca-Cusachs, Alex; Aracil-Vilar, Joaquín; Calvo-Gómez, Carlos et al.
In: Cardiovascular Therapeutics, Vol. 26, Núm. 2, 14.07.2008, pàg. 91-100.

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

TY - JOUR

T1 - Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: A randomized noninferiority trial versus torasemide immediate release

AU - Roca-Cusachs, Alex

AU - Aracil-Vilar, Joaquín

AU - Calvo-Gómez, Carlos

AU - Vaquer-Pérez, José Vicente

AU - Laporta-Crespo, Félix

AU - Rojas-Serrano, María José

AU - Guglietta, Antonio

AU - Gropper, Savion

AU - Alexeeva, Nadezhda

AU - Aranda, Pedro

AU - Ballvé, Josep Lluis

AU - Baranovsky, Andrei

AU - Boldueva, Svetlana

AU - Brotons, Carles

AU - Cano, Angel

AU - Churina, Svetlana

AU - Coca, Antoni

AU - De Teresa, Luis

AU - Divisón, Juan Antonio

AU - Dumpis, Yanis

AU - Farrés, Xavier

AU - Felip, Ángela

AU - García, Juan

AU - Gil, Blas

AU - Goloschekin, Boris

AU - Gómez, Pablo

AU - Kostenko, Victor

AU - De Coca, Enrique López

AU - Luque, Manuel

AU - Marco, Emili

AU - Martorell, Joan

AU - Milyagin, Viktor

AU - Orlov-Morozov, Alexander

AU - Parfenov, Vladimir

AU - Pavlysh, Elena

AU - Plana, Jaume

AU - Prieto, Miguel Ángel

AU - Pujol, Montserrat

AU - Rodríguez, José Carlos

AU - Sherenkov, Alexander

AU - Sobrino, Javier

AU - Sorokin, Lev

AU - Vilà, Joaquim

AU - Zobenko, Irina

AU - Zrazhesvsky, Konstantin

PY - 2008/7/14

Y1 - 2008/7/14

N2 - The efficacy of a new torasemide prolonged release (PR) formulation to torasemide immediate release (IR) was compared in a randomized noninferiority double-blind trial. Patients with newly diagnosed mild-to-moderate hypertension or unresponsive or poor tolerability to previous antihypertensive monotherapy received 5 mg/day of torasemide-PR (n = 219) or torasemide-IR (n = 223) for 12 weeks (uptitration to 10 mg/day if no response at 4 or 8 weeks). Mean diastolic blood pressure (DBP) reduction in the torasemide-PR group (11.6 ± 7.1 mmHg, 95% confidence interval [CI] 10.6-12.5) versus torasemide-IR (11.3 ± 7.5 mmHg, 95% CI 10.2-12.3) met the noninferiority criterion of a nonsided 97.5% CI lower than the preestablished margin of 2 mmHg. A significantly higher percentage of patients in the torasemide-PR group achieved adequate BP control after 8 and 12 weeks. Ambulatory 24-h BP monitoring (ABPM) measurements in a subset of 100 patients showed greater daytime SBP reductions in the torasemide-PR group (128.4 ± 9.9 mmHg vs. 133.5 ± 10.4 mmHg, P < 0.05). Safety and tolerability of both formulations were similar. © 2008 The Authors.

AB - The efficacy of a new torasemide prolonged release (PR) formulation to torasemide immediate release (IR) was compared in a randomized noninferiority double-blind trial. Patients with newly diagnosed mild-to-moderate hypertension or unresponsive or poor tolerability to previous antihypertensive monotherapy received 5 mg/day of torasemide-PR (n = 219) or torasemide-IR (n = 223) for 12 weeks (uptitration to 10 mg/day if no response at 4 or 8 weeks). Mean diastolic blood pressure (DBP) reduction in the torasemide-PR group (11.6 ± 7.1 mmHg, 95% confidence interval [CI] 10.6-12.5) versus torasemide-IR (11.3 ± 7.5 mmHg, 95% CI 10.2-12.3) met the noninferiority criterion of a nonsided 97.5% CI lower than the preestablished margin of 2 mmHg. A significantly higher percentage of patients in the torasemide-PR group achieved adequate BP control after 8 and 12 weeks. Ambulatory 24-h BP monitoring (ABPM) measurements in a subset of 100 patients showed greater daytime SBP reductions in the torasemide-PR group (128.4 ± 9.9 mmHg vs. 133.5 ± 10.4 mmHg, P < 0.05). Safety and tolerability of both formulations were similar. © 2008 The Authors.

KW - Diuretic

KW - Hypertension

KW - Toresamide

KW - Toresamide prolonged released

U2 - 10.1111/j.1527-3466.2008.00046.x

DO - 10.1111/j.1527-3466.2008.00046.x

M3 - Article

SN - 1755-5914

VL - 26

SP - 91

EP - 100

JO - Cardiovascular Therapeutics

JF - Cardiovascular Therapeutics

IS - 2

ER -

Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: A randomized noninferiority trial versus torasemide immediate release

Resum

Accés al document

Fingerprint

Com citar-ho